‘JPMorgan Chase Cut About 500 Technology And Operations Jobs This Week, Sources Say’ – CNBC

https://www.cnbc.com/2023/05/26/job-cuts-jpmorgan-chase-cut-about-500-tech-and-ops-jobs-.html JPMorgan Chase cut about 500 positions this week, mostly among technology and operations groups, according to people with

https://www.cnbc.com/2023/05/26/job-cuts-jpmorgan-chase-cut-about-500-tech-and-ops-jobs-.html

  • JPMorgan Chase cut about 500 positions this week, mostly among technology and operations groups, according to people with knowledge of the move.
  • The cuts were spread across the New York-based firm’s main divisions, said the people, who declined to be identified speaking about personnel matters.
  • The dismissals come even as JPMorgan seeks to fill about 13,000 open positions, said one of the people.
 

JPMorgan Chase cut about 500 positions this week, mostly among technology and operations groups, according to people with knowledge of the move.

The cuts were spread across the New York-based firm’s main divisions of retail and commercial banking, asset and wealth management and its corporate and investment bank, said the people, who declined to be identified speaking about personnel matters.

Like many financial firms, JPMorgan periodically trims staff during the year, even as it hires thousands more workers to fill roles. The bank has about 13,000 open positions, said one of the people.

Under CEO Jamie Dimon, JPMorgan has been in growth mode as of late, most recently by acquiring failed regional bank First Republic in a government-brokered deal. This week, JPMorgan offered positions to about 85% of First Republic’s roughly 7,000 workers.

JPMorgan had 296,877 employees as of March 31, 8% higher than a year earlier.

The bank declined to comment about its personnel decisions.

Total
0
Shares
Related Posts
Read More

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted

CRSP

Read More

Actinium Highlights Administration Of Targeted Radiotherapy Iomab-B Across Various BMT Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 SIERRA Trial At The 48th Annual ONS Congress

-  24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute

ATNM